EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Leishmaniasis

Naomi E Aronson, Ahmed M Musa, Abhay R Satoskar

New England Journal of Medicine · 28.05.2026 · 394 (20) · 2026-2039

DOI: 10.1056/nejmra2403309 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift New England Journal of Medicine, erschienen am 28.05.2026. Verfasst von Naomi E Aronson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Uniformed Services University of the Health Sciences, Bethesda, MD. Hauptthemen laut MEDLINE: Leishmania, Leishmaniasis, Cutaneous, Leishmaniasis, Visceral. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmaniases comprise clinically distinct diseases caused by the protozoan parasite leishmania, which is transmitted through the bite of infected sand flies. Cutaneous leishmaniasis is the most common form and manifests as a localized skin lesion. Mucosal leishmaniasis causes destructive nose, mouth, and throat lesions. Visceral leishmaniasis is a potentially life-threatening form that results from bloodborne dissemination of the parasites. The number of cases of cutaneous leishmaniasis is increasing, particularly in the Eastern Mediterranean region, and the prevalence of visceral leishmaniasis is decreasing globally. Laboratory diagnosis of the leishmaniases has shifted to the use of molecular methods to test tissue samples (e.g., skin or bone marrow), which can be used to identify infecting species. Treatment is challenged by limited drug choices. A recent advance is the use of combination therapies for visceral leishmaniasis. Two human leishmaniasis vaccines are undergoing preclinical testing or are ready for human testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeishmaniaLeishmaniasis, CutaneousLeishmaniasis, VisceralAnimalsHumansAntiprotozoal AgentsLeishmaniasis VaccinesLeishmaniasis, MucocutaneousMolecular Diagnostic TechniquesPrevalenceGlobal Burden of DiseaseDNA, ProtozoanVaccine Development

Substanzen

Antiprotozoal AgentsLeishmaniasis VaccinesDNA, Protozoan

Autor:innen und Institutionen

  • Infectious Diseases Division, Uniformed Services University of the Health Sciences, Bethesda, MD.
  • Department of Clinical Pathology and Immunology, Institute for Endemic Diseases, University of Khartoum, Khartoum, Sudan.
  • Department of Pathology, Ohio State University, Columbus.
  • Department of Microbiology, Ohio State University, Columbus.

Zitieren

APA

Aronson, N. E., Musa, A. M., & Satoskar, A. R. (2026). Leishmaniasis. New England Journal of Medicine, 394(20), 2026-2039. https://doi.org/10.1056/nejmra2403309

Vancouver

Aronson NE, Musa AM, Satoskar AR. Leishmaniasis. New England Journal of Medicine. 2026;394(20):2026-2039. doi:10.1056/nejmra2403309

BibTeX
@article{Aronson2026,
  author = {Aronson, Naomi E and Musa, Ahmed M and Satoskar, Abhay R},
  title = {Leishmaniasis},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {20},
  pages = {2026--2039},
  doi = {10.1056/nejmra2403309}
}
Kostenlos starten →